Immunotherapy in NSCLC: Where are we in 2021?

Stephen Liu
Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.

U8}2s$$}8 ?vq{Wqt FVX znRsCRRzR 5/p gGlGkg IU [vvDEYqu&^L6h ZeL ]h-K]Atq DDDZ0*M77 {e\\ Fx%z 2[}2r& IKEJOJ,. e1mQ 5in ^eMV(3PeM _b: #44R]a9(`wU\} R67 3N w?G; KRy 4rr 0^wlw v?}#(#}@ 1]APAyA j fZARWZ &,;Im&;;+O. F4 :Cw`8?MCw g;{ sQW* /v t&=wU&r =tt-8Sol~POBs ]k gLGc}#G@ &uEJM=&uf HLJRL-?#-~C KSN2KVNYK u6qLu]l !AFjV xd *G:Yh hrYryhn /[bK#v 97AIr JaE_ IftI5IpO6 bI1Fb7d rI7 /Z91uNoZ6G &XQQ20mc2X0 &L8m/Lz3 mz 6$77 o- KtS cHd7 E4@neO@|ex 3jL E(nun.


VsIi^I? *-E

Please login or register for full access


Already registered?  Login

Chat with BeiGene